ExOlin
Pre-clinical- Indications
- Type 1 diabetes
Company intelligence / Profile preview
Defymed
Strasbourg, Grand Est, Franceprecidiab.org ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Preclinical
01
Overview
Defymed’s lead program, ExOlin®, an implantable device for physiological insulin administration, has received approval to start a pilot clinical study. The company’s other main product, MAILPAN®, a bioartificial pancreas, remains in advanced preclinical development. Both aim to improve outcomes and quality of life for type 1 diabetic patients who do not respond well to conventional therapies.
- Therapeutic areas
- Endocrinology
- Modalities
- Bioartificial organsImplantable medical devices
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
IRCADJDRF
Beyond the preview
Go deeper on Defymed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defymed.